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Coronary Heart Disease Risks Associated with High Levels of
HDL Cholesterol
John T. Wilkins, MD, MS; Hongyan Ning, MD, MS; Neil J. Stone, MD; Michael H. Criqui, MD, MPH; Lihui Zhao, PhD; Philip Greenland, MD;
Donald M. Lloyd-Jones, MD, ScM
Background-—The association between high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) events is
not well described in individuals with very high levels of HDL-C (>80 mg/dL).
Methods and Results-—Using pooled data from 6 community-based cohorts we examined CHD and total mortality risks across a
broad range of HDL-C, including values in excess of 80 mg/dL. We used Cox proportional hazards models with penalized splines to
assess multivariable, adjusted, sex-stratified associations of HDL-C with the hazard for CHD events and total mortality, using HDL-
C 45 mg/dL and 55 mg/dL as the referent in men and women, respectively. Analyses included 11 515 men and 12 925 women
yielding 307 245 person-years of follow-up. In men, the association between HDL-C and CHD events was inverse and linear across
most HDL-C values; however at HDL-C values >90 mg/dL there was a plateau effect in the pattern of association. In women, the
association between HDL-C and CHD events was inverse and linear across lower values of HDL-C, however at HDL-C values
>75 mg/dL there were no further reductions in the hazard ratio point estimates for CHD. In unadjusted models there were
increased total mortality risks in men with very high HDL-C, however mortality risks observed in participants with very high HDL-C
were attenuated after adjustment for traditional risk factors.
Conclusions-—We did not observe further reductions in CHD risk with HDL-C values higher than 90 mg/dL in men and 75 mg/dL
in women. ( J Am Heart Assoc. 2014;3:e000519 doi: 10.1161/JAHA.113.000519)
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T he association between high-density lipoprotein choles-terol (HDL-C) and coronary heart disease (CHD) events is
inverse and linear across a large range of HDL-C (30 to
60 mg/dL) values.1,2 Over the last several decades limited
observational cohort data have suggested a possible thresh-
old effect or increased risks for CHD and total mortality
events in participants with HDL-C >80 mg/dL.3,4 However,
the sample size of individuals with very high HDL-C was very
small in most studies, limiting the ability to draw conclusions
about the risks for CHD and total mortality associated with
extremely high levels of HDL-C. Since the guideline-based use
of lipid-lowering pharmacotherapy is based on risk assess-
ment, patients with very high levels of HDL-C present a
clinical dilemma, as the CHD risk associated with HDL-C
>80 mg/dL is not well described.
The Lifetime Risk Pooling Project is a very large dataset
with extensive phenotyping that provides a unique opportunity
to study CHD risks across the full range of HDL-C values,
including those in individuals with extreme elevations in HDL-
C.5 In addition, the detailed covariate data from these cohorts
allow for adjustment for many potential confounding vari-
ables. In this study, we aimed to quantify, in unadjusted and
adjusted models, the hazards for CHD events and total
mortality in individuals with very high HDL-C. We hypothesized
that we would see independent increased hazards for CHD
events in individuals with very high levels of HDL-C when
compared with a 45 mg/dL and 55 mg/dL referent in men
and women, respectively.
Methods
Participants
The cohorts included in the analysis met the following a priori
criteria: (1) community- or population-based sampling or large
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volunteer cohort; (2) availability of at least one baseline
examination at which participants provided demographic,
personal, and medical history information and underwent
direct measurement of physiologic and/or anthropometric
variables (eg, blood pressure, weight), lipid assessment
(including HDL-C), and alcohol consumption; (3) availability
of total mortality and cardiovascular mortality data also with
ascertainment of nonfatal myocardial infarction events. We
selected the following 6 cohorts: Framingham Heart Study6
(FHS), Framingham Offspring Study (FOS),7 Cardiovascular
Health Study (CHS),8 Atherosclerosis Risk in Communities
Study (ARIC),9 Honolulu Heart Study10,11 (HHP), and the
Women’s Health Initiative12 (WHI) study. Participants were
excluded from the analysis if they had pre-existing CHD
(previous diagnosis of myocardial infarction, known angina
pectoris, a history of hospitalization for unstable angina, or
previous coronary revascularization). The Institutional Review
Board at Northwestern University approved this project.
Determination of Lipid Phenotype
Blood from each study was collected and stored at 70°C
after venipuncture until the time of analysis. To determine
HDL-C, all cohorts (except WHI) utilized centrifugation
followed by removal of all apolipoprotein B containing lipid
particles with a magnesium/dextran precipitation assay.13
HDL-C was then quantified by standardized enzymatic tech-
niques.7–9 Total cholesterol (TC) and triglycerides were
determined by direct enzymatic techniques. LDL-C was
calculated via the Friedewald equation.14 The WHI cohort
utilized the Hitachi 917 analyzer (Roche Diagnostics) for
determination of HDL-C, LDL-C, Triglycerides, and TC. This
system uses a direct enzymatic colorimetric assay for
determination of all lipid subfraction concentrations.12 Non-
HDL cholesterol was calculated as the difference between TC
and HDL-C.
Determination of Covariates
Details of demographic and traditional risk factor assessment
are presented elsewhere.6–12 Briefly, age, sex, race, smoking
status, alcohol consumption, diabetes status, anti-hyperten-
sion medication use, and lipid medication use were deter-
mined by self-report. In ARIC, medication use was confirmed
by bottle inspection. Diabetes was defined as self-reported
physician diagnosis, fasting blood sugar ≥126 mg/dL, or
diabetes medication use. A drink was defined as one serving
of alcohol (12 oz beer, 6 oz glass of wine, or 1.5 oz of hard
liquor) or as 0.6 fluid oz, 14 g, or 18 mL or ethanol depending
on the cohort. Self-reported weekly and monthly alcohol
consumption was converted to daily consumption and defined
as the equivalent of >1 drink a day for women and >2 drinks a
day for men. Systolic blood pressure was an average of 2 to 3
measurements taken while seated (supine for HHP). A
mercury sphygmomanometer was used for all blood pressure
measurements. BMI was calculated as the weight in kilograms
divided by the square of the height in meters.
Determination of Outcome
CHD events (nonfatal myocardial infarction [MI] and CHD
death) and total mortality events were ascertained using
cohort-specific criteria, as described elsewhere.6–12 Briefly,
the Framingham Heart Study adjudicated CHD events via
medical history, physical examinations, and electrocardio-
grams. All suspected CHD events were reviewed by a panel of
3 physicians, who applied established criteria for such
events.7 CHS, ARIC, HHP, and WHI generally utilized similar
criteria: myocardial infarction was defined as an evolving Q-
wave MI or cardiac pain associated with abnormal cardiac
enzymes and either an evolving ST- or T-wave pattern or new
left bundle branch block on electrocardiogram. A panel of
study physicians within each study adjudicated CHD death.
Follow-up for vital status and date of death is nearly 100%
complete in each of the cohorts.
Statistical Analyses
To examine the potential nonlinear association between
continuous HDL-C and the risks of events, we used penalized
cubic splines in Cox proportional hazards models, which can
provide nonparametric estimates for the hazard ratio of HDL-
C.15,16 The proportional hazards assumption was tested using
Schoenfeld residuals and was found to be appropriate.17,18
The hazard ratios were scaled such that the hazard ratio was
1 for the HDL-C level of 45 mg/dL and 55 mg/dL in men and
women, respectively. The follow-up time was truncated at
20 years, as there were few person-years beyond that point
for most of the cohorts. The survival models were initially
adjusted for cohort; then adjusted for age, race, systolic blood
pressure, body mass index, current smoking status, diabetes,
non-HDL-C, antihypertensive therapy, antihyperlipidemia ther-
apy, and alcohol drink status (>1 drink/day for women and >2
drinks/day for men).
Due to minor differences in mean HDL-C across cohorts
and slight differences in the measurement of HDL-C across
cohorts, we conducted a sensitivity analysis. For the sensi-
tivity analysis, data were pooled by cohort- and sex-specific Z-
scores of HDL-C. The hazard ratios were scaled such that the
hazard ratio was 1 for the HDL-C Z-Score of 0. We then re-ran
the analysis using penalized cubic splines as described above.
In an effort to further examine the effect of alcohol
consumption and smoking on elevated HDL-C and total
mortality and CHD events, we also conducted separate
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stratified (by alcohol and smoking) penalized cubic spine
models on the pooled cohort. Baseline hormone replacement
therapy (HRT) status and lipid concentrations were available in
FH, FOS, and ARIC cohorts only. To assess possible con-
founding or effect modification due to HRT in women, we ran
cohort-specific, HRT-stratified Cox proportional hazard mod-
els. We also assessed the significance of a HDL-C (continuous)
by HRT interaction term. We used separate sex-stratified
univariable Cox proportional hazard models to determine the
traditional risk factor characteristics that were associated with
CHD events in individuals with HDL-C >75 mg/dL.
A P value <0.05 was considered statistically significant,
and all statistical tests for significance were 2-tailed. Statis-
tical analyses were performed using SAS statistical software
v. 9.1. The penalized cubic spline model was implemented
using coxph and pspline functions in R version 2.14.1.
Results
Study Sample
Baseline characteristics for the 11 515 men included in the
analysis are presented in Table 1. The mean ages across all
strata of HDL-C varied from 54 to 60 years. The median HDL-
C in the highest stratum (>90 mg/dL) was 100 mg/dL. The
mean non-HDL-C, triglyceride levels, and prevalence of
cholesterol medication use were lowest in the very high
HDL-C strata. Men within the 2 highest HDL-C strata had
higher mean systolic blood pressures. When compared with
the lower strata of HDL-C (≤50 mg/dL) men in the higher
strata had lower BMI. Reported alcohol consumption and
smoking were highest in the highest strata of HDL-C at 40%
and 52%, respectively.
Baseline characteristics for the 12 925 women included in
the analysis are presented in Table 2. The mean ages across all
strata of HDL-C ranged from 55 to 58 years. The median HDL-
C in the highest stratum was 99 mg/dL. Similar to men, non-
HDL-C, triglyceride levels, and BMI were lowest in the highest
stratum. Systolic blood pressure was slightly lower across
higher HDL-C strata. The prevalence of drinking >1 drink a day
was greatest in the 2 highest strata of HDL-C. Smoking
prevalence was generally lower across higher HDL-C strata.
In men, 1825 CHD events and 3311 deaths from any cause
occurred during 139 624 person-years of follow-up. In
women, 977 CHD events and 2435 deaths from any cause
occurred during 167 622 person-years of follow-up. In men,
unadjusted total mortality rates were highest in the 4 highest
strata of HDL-C; in contrast, unadjusted CHD event rates were
highest in the 2 lowest strata of HDL-C (Table 3). In women,
unadjusted total mortality events were similar across all
Table 1. Baseline Characteristics by HDL-C Strata: Men*
HDL-C (mg/dL)
≤30 31 to 40 41 to 50 51 to 60 61 to 70 71 to 80 81 to 90 >90
N 1063 3520 3497 2058 796 335 129 117
Age, y 54.4 (9.6) 56.0 (11.1) 57.5 (12.1) 58.1 (12.2) 59.9 (12.3) 59.8 (12.7) 60.1 (11.7) 59.2 (9.7)
SBP, mm Hg 126.7 (20.0) 127.4 (19.7) 128.8 (21.0) 129.8 (21.1) 131.8 (22.5) 131.8 (20.8) 136.1 (24.9) 141.4 (26.0)
DBP, mm Hg 77.2 (11.6) 77.1 (11.6) 77.1 (11.6) 78.0 (11.6) 77.8 (12.2) 77.5 (12.0) 80.7 (12.7) 83.2 (15.0)
BMI, m/kg2 28.5 (4.0) 27.7 (4.0) 26.8 (3.7) 26.1 (3.9) 25.1 (3.7) 24.6 (4.0) 23.8 (4.4) 23.4 (3.8)
TC, mg/dL 203.1 (43.4) 209.6 (40.3) 210.4 (39.1) 212.1 (40.9) 210.4 (38.6) 215.0 (41.5) 216.3 (44.0) 220.5 (39.8)
HDL-C, mg/dL 26.4 (3.7) 35.8 (2.7) 45.0 (2.8) 54.5 (3.0) 64.5 (2.8) 75.0 (2.9) 84.5 (2.8) 104.0 (13.6)
Non-HDL-C, mg/dL 176.7 (43.6) 173.8 (40.5) 165.4 (39.2) 157.5 (40.9) 145.9 (38.6) 140.1 (41.4) 131.8 (44.0) 116.5 (36.5)
LDL-C, mg/dL 132.0 (40.8) 140.8 (36.6) 139.9 (35.4) 136.1 (38.3) 128.9 (35.0) 124.3 (37.5) 117.2 (39.3) 102.0 (34.7)
Triglycerides, mg/dL 273.9 (182.0) 219.8 (155.7) 169.9 (123.7) 147.1 (119.5) 128.5 (113.5) 114.8 (88.0) 116.0 (110.5) 76.0 (44.0)
Cholest Rx, % 5 4 3 2 2 1 2 1
HTN Rx, % 22 22 20 19 17 22 15 18
Hx DM, % 14 10 7 6 5 5 9 10
Smoker†, % 43 35 31 31 29 33 37 52
Alcohol, % 18 16 20 25 31 34 35 40
BMI indicates body mass index; Cholest Rx, cholesterol medication use; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HTN Rx, blood pressure-lowering
medication use; Hx DM, history of diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol;.
*Data are expressed as mean (SD) unless otherwise indicated.
†Smokers current.
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HDL-C strata >60 mg/dL, but death rates were higher for
individuals in lower strata (HDL-C <40 mg/dL). The unad-
justed CHD death and nonfatal MI rates were lowest in the
higher (>60 mg/dL) strata of HDL-C (Table 3).
CHD Events
The unadjusted and multivariable-adjusted cubic spline of the
log-transformed hazard ratios for CHD death and nonfatal MI
for men and women are presented in Figure. Men with HDL-C
values less than the referent had higher hazards for CHD
events (Figure – Panel A). This relationship is inverse and
linear up to an HDL-C value of 90 mg/dL. At HDL-C values
above 90 mg/dL no further reduction in CHD risk was
observed. In traditional risk factor and alcohol-adjusted
models, the point estimate was no longer significantly
different from the referent when the HDL-C >95 mg/dL
(Figure – Panel B). However, the sample size of this group is
Table 2. Baseline Characteristics by HDL-C Strata: Women*
HDL-C (mg/dL)
≤30 31 to 40 41 to 50 51 to 60 61 to 70 71 to 80 81 to 90 >90
N 282 1299 2986 3330 2325 1441 728 534
Age, y 55.2 (10.35) 56.8 (10.9) 57.2 (11.4) 57.1 (11.6) 57.4 (11.8) 57.8 (11.2) 57.9 (10.9) 58.4 (9.9)
SBP, mm Hg 128.5 (20.2) 128.9 (22.3) 126.9 (21.7) 125.8 (21.3) 125.0 (21.3) 124.7 (21.3) 125.0 (21.4) 123.2 (20.1)
DBP, mm Hg 75.0 (10.5) 75.1 (12.3) 74.0 (11.6) 73.7 (11.2) 73.2 (11.3) 73.2 (11.1) 73.2 (11.2) 72.2 (11.3)
BMI, m/kg2 28.5 (5.6) 28.7 (5.8) 27.8 (5..6) 26.7 (5.3) 25.6 (4.9) 24.9 (4.7) 24.4 (4.3) 24.0 (4.4)
TC, mg/dL 221.4 (56.6) 217.7 (46.6) 221.2 (45.0) 218.3 (41.0) 220.3 (41.5) 220.3 (41.5) 222.3 (36.4) 227.9 (37.0)
HDL-C, mg/dL 26.6 (3.6) 36.5 (2.7) 45.7 (2.8) 55.2 (2.9) 65.1 (2.8) 74.8 (2.9) 84.7 (2.7) 101.8 (10.8)
Non-HDL-C, mg/dL 194.8 (57.0) 181.3 (46.8) 175.5 (44.4) 165.9 (45.0) 153.1 (41.1) 145.5 (41.6) 137.6 (37.5) 126.1 (37.8)
LDL-C, mg/dL 147.6 (50.4) 143.8 (42.4) 144.9 (39.2) 140.0 (40.8) 130.7 (37.3) 125.0 (38.5) 118.8 (34.4) 107.4 (35.0)
Triglycerides, mg/dL 263.3 (180.6) 206.5 (135.2) 168.0 (113.5) 147.0 (101.2) 125.9 (91.5) 115.2 (82.8) 113.2 (81.2) 95.3 (66.6)
Cholest Rx, % 5 3 3 2 2 2 2 2
HTN Rx, % 30 29 26 23 21 19 18 17
Hx DM, % 18 12 8 5 3 3 2 2
Smoker†, % 45 39 33 28 25 24 24 21
Alcohol, % 17 10 10 13 16 19 23 26
BMI indicates body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total
cholesterol.
*Data are expressed as mean (SD) unless otherwise indicated.
†Smokers current.
Table 3. Sample Size and Unadjusted Event Rates* by HDL-C Strata
HDL-C (mg/dL)
≤30 31 to 40 41 to 50 51 to 60 61 to 70 71 to 80 81 to 90 >90
Men
N 1063 3520 3497 2058 796 335 129 117
Mortality event rate 21.8 22.2 22.9 24.1 29.8 31.9 32.7 43.4
CHD event rate 18.8 15.7 13.0 10.7 12.0 9.7 6.4 10.0
Women
N 282 1299 2986 3330 2325 1441 728 534
Mortality event rate 21.0 19.2 15.2 14.0 12.1 13.2 14.0 13.5
CHD event rate 8.9 9.2 7.0 6.2 4.2 3.9 4.1 3.2
CHD indicates coronary heart disease; HDL-C, high-density lipoprotein cholesterol.
*Events per 1000 person-years.
DOI: 10.1161/JAHA.113.000519 Journal of the American Heart Association 4
High HDL-C and CHD Risk Wilkins et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
substantially less (causing the very wide 95% CI) than the size
of the referent category, which likely accounts for the lack of
significance. In cohort-adjusted models, women with HDL-C
<55 mg/dL had higher hazards for CHD events; hazards for
CHD events were significantly <1 across all HDL-C values
>55 mg/dL (Figure – Panel C). In multivariable adjusted
models, the pattern of association is inverse and linear up to
HDL-C of 75 mg/dL. At HDL-C strata >75 mg/dL there
was no further reduction in the point estimate of CHD risk
(Figure – Panel D). Above HDL-C values of 85 mg/dL hazard
ratios were not significantly different from the referent in
multivariable adjusted models, though the sample size is
modest at such high levels of HDL-C, which likely accounts for
the lack of significance. In sensitivity analysis, the patterns of
association between HDL-C and CHD events were similar in
alcohol- and tobacco- and HRT-stratified models. There was
no significant HRT by HDL-C interaction term. Likewise,
pooling by cohort-specific HDL-C Z-score did not alter the
pattern of association.
We sought to describe the characteristics of men and
women with very high HDL-C who nonetheless had CHD
events during follow up. There were 392 men with HDL-C
CHD Events men (mulvariable adjusted) CHD Events women (mulvariable adjusted)
CHD Events women (cohort adjusted)CHD Events men (cohort adjusted)
A. C.
B. D.
Figure. Log hazard ratios (95% CI) for CHD events by HDL-C for men and women. CHD indicates coronary heart disease; HDL-C, high-density
lipoprotein cholesterol.
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>75 mg/dL and 32 CHD events occurred during follow-up. In
men, systolic blood pressure (HR=1.01; 95% CI 1.0, 1.03),
total cholesterol (HR=1.01; 95% CI 1.01, 1.02), and non-HDL
cholesterol (HR=1.01; 95% CI 1.00, 1.02) were significantly
associated with an increased risk for CHD events. There were
1864 women with HDL-C >75 mg/dL and 95 CHD events
that occurred during follow-up. In women, age (HR 1.1; 95% CI
1.06, 1.14), systolic blood pressure (HR 1.03; 95% CI 1.02,
1.04), diastolic blood pressure (HR=1.03; 95% CI 1.01, 1.05),
and treatment for hypertension (HR=1.71; 95% CI 1.08, 2.71)
were associated with increased risk for CHD events during
follow-up.
Total Mortality
In men, there was an unadjusted parabolic association
between HDL-C and total mortality with substantially elevated
hazards for total mortality in the highest and lowest HDL-C
categories. However, after multivariable adjustment and
further stratification by smoking status these risks were
highly attenuated among individuals with very high HDL-C.
There were no significant associations between high HDL-C
and total mortality in women.
Discussion
In this pooled analysis from 6 community-based cohorts we
did not observe a monotonic inverse linear association
between HDL-C and CHD risk at very high levels of HDL-C.
Rather, we observed evidence of a plateau effect for CHD risk
at high levels of HDL-C in men and women.
Although CHD event rates were generally lower in cohort
participants with very high HDL-C, risk for CHD events
persisted in this group as many participants with very high
HDL-C still experienced MI or CHD death during follow-up.
However, the significant associations observed between age,
blood pressure, and non-HDL-C and CHD risk suggest that
at-risk individuals with very high HDL-C are at least
partially identifiable through assessment of traditional risk
factors. We believe this observation suggests heterogeneity in
the CHD risk of individuals with very high HDL-C. Therefore,
it is important for clinicians to continue to consider the
entire spectrum of CHD risk factors, and not assume that a
very high HDL-C is automatically or fully protective against
CHD.
A recent nested case-control analysis on participant
samples from the Nurses’ Health and Health Professionals
Follow-Up Studies suggests a structural variation in HDL
particles that may mediate the atheroprotective properties of
HDL. Specifically, Jensen et al found that people with HDL
particles that contained Apolipoprotein CIII did not have the
expected inverse association between HDL-C and CHD risk.19
This finding raises the possibility that more prevalent
dysfunctional HDL particle variants in people with very high
HDL-C could explain the plateau relationship between HDL
and CHD risk observed in this study.
Interestingly, the triglyceride concentrations in Tables 1
and 2 are noticeably lower in individuals with very high HDL-C.
Higher triglyceride concentrations in individuals with very high
HDL-C suggest the possibility of decreased lipid exchange
from HDL to VLDL particles that could be mediated by
abnormalities in physiologic pathways for lipid exchange
between lipoprotein particles, eg, cholesteryl ester transfer
protein (CETP) activity.
Multiple epidemiologic studies have demonstrated a well-
known independent inverse linear association between HDL-C
and risk for CHD events across a broad range of HDL-C
concentrations <60 mg/dL.1,2 However, prior studies could
not thoroughly assess the pattern of association in people
with levels of HDL-C >80 mg/dL, due to its uncommon
occurrence. In many of these studies, when data were
examined in ordinal bins of HDL-C, the highest stratum of
HDL-C was >50 to 55 mg/dL. If a small number of cohort
participants with HDL-C >80 mg/dL were grouped with a
much larger number of participants with HDL-C values close
to 50 mg/dL, the effect of the larger numbers of participants
with HDL-C close to 50 mg/dL would dominate and could
mask a potential plateau pattern of association suggested in
our larger sample. Furthermore, careful inspection of crude
event rates presented from the Lipoprotein Phenotyping
Study reveals a small increase in the event rate for CHD at
HDL-C values >75 mg/dL.1 More recent data from the
Incremental Decrease in End Point Through Aggressive Lipid
Lowering study (IDEAL) demonstrated a modest increase in
the risk for major cardiac events in participants with HDL-C
values >80 mg/dL.4 The association became significant only
after adjustment for traditional risk factors, Apolipoprotein-A1
and Apolipoprotein-B concentrations. Unlike our study, they
were not able to adjust for alcohol consumption in the IDEAL
study, which, given the confounding effects of ethanol abuse
on HDL-C and CHD events, was a major limitation of their
analysis.
Our study benefited from a large aggregation of multiple
community-based samples and well-phenotyped cohorts. As
mentioned above, this sample allows for adjustment for many
potential confounding variables—most notably alcohol. To the
best of our knowledge, no other such analysis has been
performed. With the pooling of multiple cohorts, it is possible
that cohort-specific or birth cohort effects are present.
However, all individual-level cohort data were reviewed and
pooled only after similar patterns of association were seen
between cohorts. Unfortunately we are unable to obtain
sufficient data to adjust for the effects of dietary fat intake
DOI: 10.1161/JAHA.113.000519 Journal of the American Heart Association 6
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and frequency of aerobic exercise on HDL-C values and CHD
events.
In summary, we observed strong evidence of a plateau
effect in terms of CHD risk reduction for men and women with
very high levels of HDL-C. Thus, CHD risk persists even among
people with very high HDL-C. These data suggest that
clinicians should have continued vigilance about the detec-
tion, avoidance, and treatment of traditional risk factors in
this patient population. We believe these data support the
possibility of diversity and complexity in the function of HDL in
constitutive human physiology. Further research is needed
into whether specific biologic mechanisms related to health
outcomes vary with HDL-C level.
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